Trimetazidine to Reduce Myocardial Fibrosis-Competing Interests with SGLT2 Inhibitors?
Cardiovasc Drugs Ther
.
2023 Sep 13.
doi: 10.1007/s10557-023-07508-2.
Online ahead of print.
Authors
Tyler B Moran
1
,
Masafumi Kitakaze
2
,
Yochai Birnbaum
3
Affiliations
1
The Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.
2
Hanwa Memorial Hospital, Osaka, Japan.
3
The Section of Cardiology, Baylor College of Medicine, Houston, TX, USA. ybirnbau@bcm.edu.
PMID:
37702833
DOI:
10.1007/s10557-023-07508-2
No abstract available
Publication types
Editorial